Authors:
C Swanton, Z Szallasi, JD Brenton, J Downward
Journal name: 
Breast Cancer Res
Citation info: 
10(5):214
Abstract: 
The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen. Given the limited power of microarray signatures to predict therapeutic response in associative studies of small clinical trial cohorts, the use of functional genomic data combined with expression or sequence analysis of genes and microRNAs implicated in drug response in human tumours may provide a more robust method to guide adjuvant treatment strategies in breast cancer that are transferable across different expression platforms and patient cohorts.
DOI: 
http://doi.org/10.1186/bcr2159
Research group: 
Brenton Group
E-pub date: 
31 Aug 2008